Overcoming oxaliplatin resistance and toxicity in colorectal cancer: the emerging role of lipid-based nanocarriers

To provide a comprehensive overview of lipid-based nanocarriers for oxaliplatin (OXA) delivery in colorectal cancer (CRC), with emphasis on their potential to improve pharmacokinetics, enhance tumour accumulation, enable controlled drug release, and overcome OXA resistance.

Relevant literature on OXA, CRC, lipid-based nanocarriers, drug resistance, tumor targeting, co-delivery, and stimuli-responsive delivery systems was reviewed. The review focused on liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid micelles, and advanced lipid-based systems, including passive and active targeting strategies and approaches for overcoming therapeutic resistance.

Lipid-based nanocarriers demonstrated potential to improve OXA delivery through enhanced tumour accumulation, controlled release, prolonged drug exposure, and improved intracellular uptake. Active targeting using folate, CD44, peptides, or antibodies, along with co-delivery, tumor microenvironment modulation, and externally triggered release, may further enhance therapeutic efficacy and help overcome multidrug resistance. However, most evidence remains preclinical, and challenges including formulation stability, tumor heterogeneity, large-scale manufacturing, and regulatory requirements limit clinical translation.

Lipid-based nanocarriers represent a promising strategy for improving OXA therapy in CRC, particularly for addressing toxicity, drug resistance, and inefficient tumor delivery. Nevertheless, the limited clinical evidence for OXA-loaded lipid nanocarriers necessitates further pharmacokinetic, toxicological, manufacturing, and well-designed clinical studies before their clinical effectiveness can be established.

Abstract from PubMed (PMID 43008077). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.